FLR
58
3
EXC
53
-3
MSFT
50
3
NOC
43
11
EQIX
64
2
APD
59
2
NWS
66
-3
VRSN
53
-4
BAC
53
3
HOG
35
2
WM
79
3
TROW
56
5
F
58
11
EQT
57
-2
PAYX
53
2
CL
58
2
CA
38
6
MHK
49
4
MRK
25
-2
HRB
57
5
FLR
58
3
EXC
53
-3
MSFT
50
3
NOC
43
11
EQIX
64
2
APD
59
2
NWS
66
-3
VRSN
53
-4
BAC
53
3
HOG
35
2
WM
79
3
TROW
56
5
F
58
11
EQT
57
-2
PAYX
53
2
CL
58
2
CA
38
6
MHK
49
4
MRK
25
-2
HRB
57
5
Financhill
Back

ImmunoPrecise Antibodies 10K Form

Sell
13

IPA
ImmunoPrecise Antibodies

Last Price:
0.40
Seasonality Move:
16.89%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive IPA News And Ratings

See the #1 stock for the next 7 days that we like better than IPA

IPA Financial Statistics

Sales & Book Value

Annual Sales: $18.16M
Cash Flow: $-1.52M
Price / Cash Flow: 0
Annual Sales: $0.87
Price / Book: 0.44

Profitability

EPS (TTM): -0.78030
Net Income (TTM): $-20.32M
Gross Margin: $8.93M
Return on Equity: -61.97%
Return on Assets: -39.4%

ImmunoPrecise Antibodies Earnings Forecast

Key ImmunoPrecise Antibodies Financial Ratios

  • The Gross Profit Margin over the past 17 years for IPA is 49.16%.
  • The Selling, General & Administrative Expenses for IPA have been equal to 78.04% of Gross Profit Margin.
  • The Research & Development expenses have been 16.49% of Revenue.
  • The Interest Expense is -0.07% of Operating Income.
  • The Net Earning history of IPA is -110.85% of Total Revenues.
  • Per Share Earnings over the last 29 years have been positive in 16 years.

ImmunoPrecise Antibodies Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Life Sciences Tools & Services
Sector: Health Care
Current Symbol: IPA
Website: ipatherapeutics.com

Debt

Debt-to-Equity Ratio: 0.08
Current Ratio: 0.99
Quick Ratio: 0.67

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

IPA Technical Analysis vs Fundamental Analysis

Sell
13
ImmunoPrecise Antibodies (IPA) is a Sell

Is ImmunoPrecise Antibodies a Buy or a Sell?